Skip to Main Content

Go to Main Navigation

High Sensitivity TSO500 Detection of Somatic Variants in Matched FFPE and Plasma

Small Scientist on October 10, 2020

Date: November 10. Time: 11:00AM EST.

Discovery Life Sciences has developed a new bundled solution leveraging Illumina’s TruSight Oncology 500 (TSO00) Solid Tumor (FFPE) and cfDNA that delivers actionable, reliable NGS data across matched FFPE tumor and plasma biospecimens. These biomarkers can have relevance for disease detection, disease progression and relapse over time, and can indicate potential response to treatment for use in the discovery, development and validation of liquid biopsy tests and targeted oncology therapies.

Watch Video